Karen Akinsanya
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · Schrodinger, Inc.
- 2026
- Sep 21, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Karen Akinsanya files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ramy Farid - $1.17M in SDGR purchases and sales in the last 12 months
- Rachit Jain - $45K in SDGR purchases and sales in the last 12 months
- Robert Lorne Abel - $33K in SDGR purchases and sales in the last 12 months
- Margaret Dugan - $29K in SDGR purchases and sales in the last 12 months
- Kenneth Patrick Lorton - $28K in SDGR purchases and sales in the last 12 months
- Jenny Herman - $28K in SDGR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Karen Akinsanya?
Karen Akinsanya is a corporate insider, tracked as President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships of Schrodinger, Inc. (SDGR). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Karen Akinsanya submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Karen Akinsanya been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($972K) across all tracked filings.
